Prem

A tiny bee just did what chemotherapy couldn't. Scientists in Australia discovered that honeybee venom can wipe out 100% of aggressive breast cancer cells in under 60 minutes. And the healthy cells around them? Barely touched. The breakthrough came from Dr. Ciara Duffy and her team at the Harry Perkins Institute of Medical Research, working alongside the University of Western Australia. They tested venom drawn from 312 honeybees and bumblebees across Australia, Ireland, and England. The target: triple-negative breast cancer and HER2-enriched breast cancer. Two of the deadliest, most stubborn forms of the disease. The weapon: melittin. The same tiny peptide that makes a bee sting burn. At one specific dose, melittin tore through cancer cell membranes completely within an hour. Within just 20 minutes, it shut down the chemical signals cancer cells need to grow and multiply. Bumblebee venom, which lacks melittin, did nothing. Zero effect, even at high concentrations. Scientists then recreated melittin synthetically in the lab and got almost identical results, meaning no bees need to be harmed to develop the therapy. Published in the peer-reviewed journal npj Precision Oncology, the findings are still early-stage. Human trials haven't happened yet. But one thing is clear. Nature has been hiding answers in plain sight all along, sometimes inside the smallest creatures on Earth. Source: Harry Perkins Institute of Medical Research / npj Precision Oncology (Dr. Ciara Duffy et al.)

SciInFocus's tweet photo. A tiny bee just did what chemotherapy couldn't.

Scientists in Australia discovered that honeybee venom can wipe out 100% of aggressive breast cancer cells in under 60 minutes.
And the healthy cells around them? Barely touched.

The breakthrough came from Dr. Ciara Duffy and her team at the Harry Perkins Institute of Medical Research, working alongside the University of Western Australia.
They tested venom drawn from 312 honeybees and bumblebees across Australia, Ireland, and England.

The target: triple-negative breast cancer and HER2-enriched breast cancer. Two of the deadliest, most stubborn forms of the disease.
The weapon: melittin. The same tiny peptide that makes a bee sting burn.

At one specific dose, melittin tore through cancer cell membranes completely within an hour. Within just 20 minutes, it shut down the chemical signals cancer cells need to grow and multiply.
Bumblebee venom, which lacks melittin, did nothing. Zero effect, even at high concentrations.

Scientists then recreated melittin synthetically in the lab and got almost identical results, meaning no bees need to be harmed to develop the therapy.

Published in the peer-reviewed journal npj Precision Oncology, the findings are still early-stage. Human trials haven't happened yet.

But one thing is clear. Nature has been hiding answers in plain sight all along, sometimes inside the smallest creatures on Earth.

Source: Harry Perkins Institute of Medical Research / npj Precision Oncology (Dr. Ciara Duffy et al.)

49K

19K

18K

Who to follow

TrendSniperStocks - Vardhan

@CaVardhanCa

CA, Angel Investor, STOCK Directional, XAUUSD, Tweets are Personal & educational purpose only, Spreading Positivity. ❤️

Vishal Mehta, CMT

@vishalmehta29

📈 Algo Trader | Market Educator 💡 Decode Markets with Step-by-Step Learning 🎯 Trade Smarter. Invest Better. 🌐 Learn • Apply • Grow

Pawan Arora

@pawanaroraleo

Stopped Tracking after winning 20+ 60 Day Challenges Zerodha 60D Challenge Interview https://t.co/5tKSFlJsWJ

PremKV09 retweeted

Nithin Kamath

@Nithin0dha

4 months ago

MTF books are growing across brokers despite the broader markets going nowhere. This isn't like the Korean markets, for example, where the markets are up 150% in the last year alone, and people are borrowing to ride that rally. Our situation is different. The big risk with MTF is the risk of the stock becoming illiquid in case there's a sharp market fall. If a stock moves more than the margin provided (say 20%), the bad debit is on the broker. The odds of recovering a loss from a customer aren't that great. The risk shoots up when the collateral is stocks. A customer pledges Stock A, gets 80% margin on it, and uses that to take further positions worth 400% in the same stock. If that stock is a mid or small-cap stock, circuits kick in, and there's simply no exit if markets turn around. Nearly 50% of the entire industry MTF book is non-F&O stocks. While we still don’t allow collateral margin for buying MTF, competitive pressure would mean we will have to. There's significant risk on the customer, but also on the broker. While our MTF book has grown meaningfully over the last 16 months, it's still only about 25% of our networth. For some brokers, this number could be closer to 500% which is the maximum regulator allows. If markets crash, brokers could end up holding losses from MTF positions they can't exit and that puts the entire ecosystem at risk. MTF seems like easy money for the brokers. But the Risk Management team at brokers has to make sure that on one bad day, you don't give it all back. 😬

Nithin0dha's tweet photo. MTF books are growing across brokers despite the broader markets going nowhere. This isn't like the Korean markets, for example, where the markets are up 150% in the last year alone, and people are borrowing to ride that rally. Our situation is different.

The big risk with MTF is the risk of the stock becoming illiquid in case there's a sharp market fall. If a stock moves more than the margin provided (say 20%), the bad debit is on the broker. The odds of recovering a loss from a customer aren't that great.

The risk shoots up when the collateral is stocks. A customer pledges Stock A, gets 80% margin on it, and uses that to take further positions worth 400% in the same stock. If that stock is a mid or small-cap stock, circuits kick in, and there's simply no exit if markets turn around. Nearly 50% of the entire industry MTF book is non-F&O stocks.

While we still don’t allow collateral margin for buying MTF, competitive pressure would mean we will have to. There's significant risk on the customer, but also on the broker. While our MTF book has grown meaningfully over the last 16 months, it's still only about 25% of our networth. For some brokers, this number could be closer to 500% which is the maximum regulator allows.

If markets crash, brokers could end up holding losses from MTF positions they can't exit and that puts the entire ecosystem at risk.

MTF seems like easy money for the brokers. But the Risk Management team at brokers has to make sure that on one bad day, you don't give it all back. 😬

969

119

249

239K

PremKV09 retweeted

Neyazuddin Ansari

@riyazz_ai

4 months ago

Instead of watching an hour of Netflix, watch this 1 hour Yale lecture. It will teach you more about options trading and the exact models hedge funds use than most people learn in their entire careers on Wall Street.

190

438

36K

Prem @PremKV09

5 months ago

@kirubaakaran Well said. ,KIRU!

Prem @PremKV09

6 months ago

@Rishikesh_ADX Daru , gutka,

Prem @PremKV09

6 months ago

@karthikrangappa HODL

165

Prem @PremKV09

6 months ago

@JakeraChoudhury Average karlo!

Prem @PremKV09

6 months ago

@hvgoenka Disagree with 1. , sirji.

PremKV09 retweeted

Kirubakaran Rajendran

@kirubaakaran

7 months ago

You don't need to read 20+ quantitative trading books. These 3 FREE sites are worth more than an entire bookshelf: 1. SSRN (https://t.co/wCQsaEfJP4) → The world's largest repository of academic research papers → Thousands of trading & investing papers from PhDs, hedge fund managers, and professors → Filter by topic: momentum, mean reversion, factor investing, risk management → Read the actual research before it becomes a bestselling book 2. Quantocracy (https://t.co/5Ha2ReBCwk) → A curated mashup of the best quantitative trading blogs on the internet → Daily updated links from top quant bloggers and researchers → Covers everything: backtesting, strategy development, risk premia, stat arb → Think of it as your daily quant newspaper 3. Alpha Architect Blog (https://t.co/gO0gFJbRN9) → Run by Dr. Wes Gray (PhD from UChicago, studied under Nobel laureate Eugene Fama) → Academic research translated into plain English for practitioners → Deep dives on value, momentum, factor investing & behavioral finance → Bridges the gap between ivory tower research and real-world trading Most trading books are just recycled versions of what's already available on these 3 sites. The difference? These are constantly updated with the latest research. Bookmark them. Read them daily. 🔗 https://t.co/wCQsaEfJP4 🔗 https://t.co/5Ha2ReBCwk 🔗 https://t.co/gO0gFJbRN9